ASSET

Asset Pharmaceuticals was a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of sleep disorders and other central nervous system conditions. The company's primary asset was Silenor (doxepin), which was developed for the treatment of insomnia characterized by difficulty with sleep maintenance. Asset Pharmaceuticals was acquired by Pernix Therapeutics in 2011, which integrated the company's portfolio to expand its presence in the CNS market. The acquisition provided Pernix with the rights to Silenor, a non-scheduled sleep medication that addresses a significant unmet need in the insomnia treatment landscape.